Menu

Kurt MÜLLER

OFTRINGEN

En résumé

Mes compétences :
Consulting
Decision Maker
Economy
HTA
MARKET ACCESS
Pricing

Entreprises

  • PharmaLevers GmbH - Principal & Managing Director

    2011 - maintenant pharmaLevers GmbH is a market access and reimbursement consulting firm for the pharmaceutical, medical device and health care industries. Focus on value transformation to the payer and decision makers’ perspective.

    - Optimizing market access process
    - Bridging and aligning stakeholder’s value perception
    - Translating pharmacoeconomic results into the payer and decision
    makers perspective
    - Enabling sales team to value based selling

    pharmaLevers GmbH is offering the following Services:
    o Market Access
    o Payer Marketing
    o HEOR Value Translation
    o Pricing & Reimbursement
    o Policy Analysis
    o HTA Lever
  • Zimmer GmbH - Senior Market Access, Policy & Reimbursement Manager EMEA

    Haifa 2010 - 2011 this European HQ Position with focus on market access in Central Europe is embedded in a global matrix organization. Key task is to accelerate and optimize market access, reimbursement and market penetration by creating stakeholder specific value messages based on clinical and health economic evidence.

    - Evaluation and interpretation of DRG’s and Coding
    - Due diligence for innovative MedTec opportunities
    - Creating value messages and dossiers
    - Special focus on HTA
    - Eucation of German and Swiss field force in health care issues,DRG’s
    and Health Economics
  • Mepha Pharma AG - Manager Pharmaceutical Policy

    2006 - 2009 - Advice and policy making for pharmaceutical economics and policies
    for the Swiss Generic Association INTERGENERIKA
    - Management of national and international price comparison studies
    e.g. price comparison of Switzerland, Germany, France, Italy and Austria
    - Comparison of the UK, French, German and Swiss Health Care and Generic Market
    - Critical appraisals of international price comparison studies e.g. IMS,
    EFPIA, OFT (UK), Eurostat
    - Evaluation of pharmaceutical policies across Europe especially in the
    area of pricing & reimbursement and rebate & discount
  • Deloitte Consulting - Senior Consultant

    Puteaux 1999 - 1999 -Evaluation of the Swiss Health Care market as an European pilot to investigate whether it would be worthwhile to enter the European health care consulting business

    - Evaluation of Deloitte’s methodologies for European suitability
    - Project on sales force effectiveness
    - Benchmark study how “Big Pharma” is managing small markets in Africa,
    Middle East and CEE
  • Arcovita AG ( Payer) - Head Pharmaceutical Department

    1997 - 1998 the Swiss Managed Care Organization of two major sickness funds covering one third of the Swiss population with an annual drug budget of 500 Mio USD

    - Design and implementation of new, innovative health care solutions to
    improve quality, outcome and costs

    - US Managed Care study visits of J&J, SKB, Lilly, BMS, S-P, Merck
    - Working in a high level interdisciplinary team with physicians
    (surgery, prevention, GP’s), insurance-, economy-, sociology- and
    marketing- experts
    - Management of a mail order pharmacy
    - Pricing studies on PPI’s with basic HTA approach
  • F. Hoffmann La Roche - Product- and Medical Manager

    1991 - 1996 - Responsible for Biotech products in the area of oncology, viral hepatitis
    and HIV
    - Marketing launch of Interferon-alpha (on a indication basis),
    Interleukin-2, Ganciclovir, Saquinavir, Zalcitabine and Tretinoin
    - Implementing global ex-factory price for a HIV drug(first proteinase inhibitor)
    - In-licensing Interleukin-2 from EuroCetus and generating sales without
    federal approval and reimbursement
    - Design and implementation of 14 clinical trials

Formations

Pas de formation renseignée

Réseau

Annuaire des membres :